Earnings Call: H2 2023

Oct 16, 2023

My name is Liz Dixon, and I'm the CFO at Tristel plc. Today, we've released our preliminary results for the year ending 30th of June 2023. We're reporting 22% revenue growth, which has come from all areas of the business, and 37% profit growth. We will pay a final dividend of 7.88p on the 22nd of December, making our full-year payout 10.5p, a 10% increase on last year, and we've changed our dividend policy to increase annually by a minimum of 5%. In June, we received clearance from the U.S. FDA to sell Tristel ULT, our high-level disinfecting foam for ultrasound, and have made first sales of the product in the United States. In addition, our ophthalmic high-level disinfectant, Duo OPH, is now selling in Canada, and we've submitted to Health Canada the dossier for Tristel ULT. We have a pipeline of new products in development and making their way to market. So all in all, we have a significant growth opportunity ahead of us, and in this set of results, we are delivering upon our growth plan. We remain profitable, cash generative, and debt-free, and we believe we have a very exciting future ahead of us. I hope to see you during our institutional and private shareholder presentations over the course of this week. Thank you.